Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$14.25
-6.8%		$20.49
$14.00
▼
$27.31
$2.66B1.123.29 million shs2.86 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$9.18
-8.2%		$8.57
$1.95
▼
$12.43
$9.73B0.0215.89 million shs21.48 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$449.74
-2.2%		$515.06
$393.61
▼
$615.00
$10.39B-1.04283,726 shs364,533 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$63.62
-2.5%		$61.14
$39.87
▼
$90.75
$9.47B1.233.60 million shs3.25 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.00%-14.36%-21.10%-39.97%-13.79%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
0.00%-12.65%+8.51%+19.53%+255.81%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%-4.67%-15.84%-18.74%+3.76%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%-10.87%+5.38%+13.20%+44.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$14.25
-6.8%		$20.49
$14.00
▼
$27.31
$2.66B1.123.29 million shs2.86 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$9.18
-8.2%		$8.57
$1.95
▼
$12.43
$9.73B0.0215.89 million shs21.48 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$449.74
-2.2%		$515.06
$393.61
▼
$615.00
$10.39B-1.04283,726 shs364,533 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$63.62
-2.5%		$61.14
$39.87
▼
$90.75
$9.47B1.233.60 million shs3.25 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.00%-14.36%-21.10%-39.97%-13.79%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
0.00%-12.65%+8.51%+19.53%+255.81%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%-4.67%-15.84%-18.74%+3.76%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%-10.87%+5.38%+13.20%+44.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.75
Moderate Buy$33.07132.08% Upside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.71
Moderate Buy$16.0074.29% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$699.2055.47% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.67
Moderate Buy$110.5073.69% Upside

Current Analyst Ratings Breakdown

Latest DYN, IBRX, MDGL, and PCVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/15/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/15/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$15.00
10/14/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$12.00 ➝ $14.00
10/14/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$16.00
10/14/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$735.00
10/12/2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$120.00
10/6/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/5/2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$116.00 ➝ $125.00
10/5/2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$89.00
10/5/2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$110.00 ➝ $122.00
(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.81 per shareN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$113.29M85.88N/AN/A($0.51) per share-18.00
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$1.28B8.09N/AN/A$26.54 per share16.95
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$20.51 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.33N/AN/AN/AN/A-64.30%-50.33%11/4/2026 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$0.97N/AN/AN/A-598.55%N/A-51.65%11/3/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A83.59N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$766.63M-$7.63N/AN/AN/AN/A-37.56%-33.62%11/3/2026 (Estimated)

Latest DYN, IBRX, MDGL, and PCVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.9122N/AN/AN/AN/AN/A
11/3/2026Q3 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.07N/AN/AN/A$59.23 millionN/A
11/3/2026Q3 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$0.8345N/AN/AN/A$405.27 millionN/A
11/3/2026Q3 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$2.11N/AN/AN/A$12.50 millionN/A
8/5/2026Q2 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$2.06-$1.97+$0.09-$1.97$12.50 millionN/A
8/4/2026Q2 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.22-$0.14-$0.22$49.70 million$51.24 million
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
7/29/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7488-$1.08-$0.3312-$1.08N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.28
12.02
12.02
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
5.72
5.70
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
5.72
5.72

Institutional Ownership

CompanyInstitutional Ownership
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%

Insider Ownership

CompanyInsider Ownership
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
66.10%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
258186.75 million169.08 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
6911.06 billion359.28 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
91523.10 million19.04 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
507148.81 million143.89 millionOptionable

Recent News About These Companies

Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated “Moderate Buy” by Sell-Side Brokerages
October 18 at 5:00 AM  |  defenseworld.netD
Vaxcyte, Inc. (NASDAQ:PCVX) Stock Has Average Target Price of $110.50 According to Analysts
October 18 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31129728
Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated "Moderate Buy" by Sell-Side Brokerages
October 18 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vaxcyte-inc-nasdaq-pcvx-stock-rated-moderate-buy-by-sell-side-brokerages-2026-10-18/
Cantor Fitzgerald sets USD 120.00 target for Vaxcyte stock
October 17 at 3:46 PM  |  ad-hoc-news.deA
Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program Advances
October 16 at 5:36 PM  |  rttnews.comhttps://www.rttnews.com/3699692/show-me-the-money-vaxcyte-delivers-100-gains-as-pneumococcal-vaccine-program-advances.aspx
Vaxcyte stock rises 6.82 percent to EUR 58.75 after-hours
October 16 at 1:16 AM  |  ad-hoc-news.deA
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
October 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3006993/wall-street-analysts-think-vaxcyte-pcvx-could-surge-75-6-read-this-before-placing-a-bet?cid=cs-stocknewsapi-ft-fundamental_analysis|consensus_price_target-3006993
Vaxcyte (NASDAQ:PCVX) Stock Keeps Overweight Rating at Cantor Fitzgerald
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110296
Vaxcyte (NASDAQ:PCVX) Earns "Overweight" Rating from Cantor Fitzgerald
October 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-vaxcyte-nasdaq-pcvx-earns-overweight-rating-from-cantor-fitzgerald-2026-10-12/
Leerink Partners Reaffirms Their Buy Rating on Vaxcyte (PCVX)
October 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PCVX/pressreleases/5675480/leerink-partners-reaffirms-their-buy-rating-on-vaxcyte-pcvx/
Vaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock sale
October 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31108213
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters ...
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxcyte-announces-closing-1-15-200500578.html
Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data
October 9, 2026  |  rttnews.comhttps://www.rttnews.com/3697945/weekly-buzz-rhhby-nvs-pfe-win-fda-nod-crbu-scales-back-pcvx-abbv-report-positive-trial-data.aspx
Vaxcyte (NASDAQ:PCVX) Stock Jumps 8.7% - What's Next?
October 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vaxcyte-nasdaq-pcvx-stock-jumps-87-whats-next-2026-10-09/
Vaxcyte (NASDAQ:PCVX) Stock: Insider Jim Wassil Sells 18,000 Shares
October 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31102609
Vaxcyte (NASDAQ:PCVX) Stock: Insider Elvia Cowan Sells 19,000 Shares
October 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31102569
Guggenheim raised target for Vaxcyte stock from USD 116.00 to USD 125.00
October 8, 2026  |  ad-hoc-news.deA
Why Vaxcyte (PCVX) Is Getting Attention Again
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-vaxcyte-pcvx-getting-attention-181517847.html
Latham Advises on Vaxcyte’s Concurrent Public Offerings of Common Stock, Pre-Funded Warrants, and Convertible Senior Notes
October 8, 2026  |  legaldesire.comL
Vaxcyte (NASDAQ:PCVX) EVP Sells $1,561,320.00 in Stock
October 8, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pcvx-insider-buying-and-selling-2026-10-08/
Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Stock
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-vaxcyte-nasdaq-pcvx-evp-jim-wassil-sells-18000-shares-of-stock-2026-10-07/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Digital illustration of glowing servers, cloud icons, and data charts connected by light streams, symbolizing cloud computing and data networks.
3 Software Stocks Rebounding as AI Fears Give Way to Growth
By Leo Miller | September 21, 2026
Worker in a safety vest and hard hat inspects steel beams inside a metal fabrication warehouse near rail cars.
Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong
By Chris Markoch | September 22, 2026
Illuminated McDonald's golden arches sign in front of a modern restaurant building at sunset.
McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
By Sam Quirke | September 30, 2026
Inhibrx logo overlaid on a laboratory scene with vials, pipettes, and a computer screen showing a protein model.
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
By Jeffrey Neal Johnson | October 2, 2026
Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$14.25 -1.04 (-6.80%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$14.40 +0.15 (+1.02%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$9.18 -0.82 (-8.20%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$9.20 +0.02 (+0.17%)
As of 10/16/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$449.74 -10.07 (-2.19%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$449.75 +0.01 (+0.00%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$63.62 -1.65 (-2.53%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$62.86 -0.77 (-1.20%)
As of 10/16/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas